AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE THAT KARMA BIOTECHNOLOGIES WILL RECEIVE THE SECOND AMGEN GOLDEN TICKET

Jan 10

THOUSAND OAKS, Calif., Jan. 10, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and BioLabs LA at the Lundquist Institute today announced that Karma Biotechnologies has been awarded the second Amgen Golden Ticket in Southern California. Karma Biotechnologies will receive one year of lab space at BioLabs LA at the Lundquist Institute (TLI) as well as additional facility benefits and connections to Amgen's scientific and business leaders.

The Amgen Golden Ticket winner was chosen by an internal team of Amgen scientific leaders at a virtual pitch event. Five finalists pitched their business plans before Amgen's internal committee that evaluated the strength and novelty of their scientific rationale, subject matter expertise and business plan viability. This is the second of three Amgen Golden Tickets to be awarded through 2023 to help accelerate life science start-ups in Southern California.

READ FULL ARTICLE HERE

Arati Desai

AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE THAT KARMA BIOTECHNOLOGIES WILL RECEIVE THE SECOND AMGEN GOLDEN TICKET

Jumpstart Nova: First Venture Fund Dedicated to Black Founded and Led Healthcare Companies Launches

Bioparker Corporation delivers innovation, interoperability solutions, and secure remote physiological monitoring on a mission to revolutionize the healthcare industry.